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1  | INTRODUC TION
The burgeoning use of filling materials has brought with it an increas-
ing interest in safety aspects of these agents. Although well-toler-
ated in general, there are serious albeit rare adverse reactions that 
demand attention.
2  | ADVERSE RE AC TIONS
Adverse reactions to filler materials may be divided into vascular1,2 
and nonvascular issues.3,4
The vascular issues have been well-described. They consist of 
the following:
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Abstract
Background: Tissue fillers are generally safe and well tolerated by patients. However, 
complications do occur and may be very severe, such as intravascular injection (with 
occasional residual tissue loss, visual and neurological sequelae) and late nodularity 
and swelling. Methods to lessen the likelihood of complications have been the sub-
ject of much recent literature. Depth of injection has been identified as a key safety 
consideration.
Patients/Methods: The role of injection of facial filler into the muscular layer of the 
face is explored in this article. Literature was explored using available search facilities 
to study the role of injections in or around this layer in the production of significant 
adverse reactions.
Results: A body of literature seems to suggest that injection into mimetic muscula-
ture of the face especially the musculature in the periorbital and perioral regions is 
prone to adverse reactions.
Conclusions: Injection of agents into the perioral and periorbital mimetic muscular 
layer may produce, product clumping, displacement, and tendency to late nodularity 
and swelling. It also risks intravascular injection as compared to injection of other lay-
ers of the face. Injection into the mimetic muscles especially the sphincteric muscles 
should be avoided to minimize the risk of complications.
K E Y W O R D S
COVID-19, mimetic muscles, orbicularis oculi, orbicularis oris, Tissue fillers
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• Minor bruising and ecchymosis from transient contact with or 
puncture of the prevailing vasculature
• True intravascular injection and embolization of fillers with tissue 
ischemia in the angiosome distribution of the vascular occlusion.5 
Dependent on the exact anatomy of the obstruction, tissue loss 
may be cutaneous only and/or involve deeper structures
• Distant embolization of fillers, in some individuals, may result in 
partial or complete unilateral and rarely bilateral visual loss and 
neurological deficit
Nonvascular issues may include:
• Misplacement or over correction often by poor injection tech-
nique or product choice
• Inadvertent placement into the retroorbital space
• Migration of a high G prime filler from the cheek into the tear 
trough region.
• Frank sepsis, which is serious but rare and usually seen in the con-
text of a break in sterile technique or patient-related factors such 
as poor local barrier function with altered local skin microbiome
Recently, the problem of delayed or late reactions to fillers has 
been more frequently reported and has been the subject of multiple 
consensus documents. These reactions include the following:
• Late noninflammatory appearing nodules/swelling- occasionally 
filler material—especially in the infraorbital zone sometimes many 
years post filler injection. Many theories have been asserted for 
this late occurrence, but most rely on the interplay of the orbicu-
laris function and the lack of natural dissolution of product in the 
periorbital area
• Evanescent and sometimes recurrent noninflammatory and in-
flammatory reactions appearing at times of heightened immune 
activity such as viral infections, which are common in both perior-
bital and perioral regions
• More fixed and problematic noninflammatory and inflammatory 
reactions which may arise weeks or months post injection. These 
would appear to be an interplay between the presence and me-
tabolism of the filler, infection, and host inflammation. It is prob-
able that host factors influence all of these with the reaction to 
infection, extent of the inflammatory reaction and the metabo-
lism of the filler all possibly varying in different individuals
3  | THE PERIOR AL AND PERIORBITAL 
MUSCUL ATURE
The orbicularis muscles surrounding the eyes and the mouth are similar 
in many respects. They both function to maintain or coordinate open-
ing and closing functions of the eyes and mouth, and they both con-
tribute to nonverbal communication and age determination, through 
their insertion into the dermis for expression and wrinkle production. 
They both fuse and coordinate with surrounding muscles to enable the 
multiple coordinated actions required for their basic functions as well 
as their role in expressions in both verbal and nonverbal forms.
They differ in a number of aspects. The orbicularis oculus mus-
cle is more of a true sphincteric muscle.6 Its functions are to close 
the eyelid and assist in pumping the tears into the nasolacrimal 
system. The orbicularis oculus muscle is a large muscle with three 
components. The outermost is the orbital component under volun-
tary control to allow expressions such as closing the eye, winking 
and smiling, the next section moving inward toward the eye is the 
pre-septal component which functions to squeeze the eyes shut ei-
ther by voluntary or involuntary blink response means and the in-
nermost pre-tarsal that keeps the eyelids opposed during sleep. The 
orbital component attaches medially to the medial canthal tendon 
and periosteum whereas the pre-septal and pre-tarsal components 
divide medially into deep and superficial heads before insertion. 
Laterally, the muscle attaches to the lateral canthal tendon, raphe, 
and surrounding tissues.
The orbicularis oris muscle has no periosteal or bony insertions 
and is not a true sphincteric muscle being made of four cooperating 
quadrants. It also has two layers—a deep layer acting as a constrictor 
cooperating in mastication and the superficial muscle layer related 
to speech and facial expressions. Much of the attachment of the 
orbicularis oris is to the modiolus bilaterally and to the muscles of 
expression for the superficial component.7
4  | METHODS
Literature search databases (PubMed, Ovid, and Google Scholar) 
were examined for articles on mimetic muscles, intramuscular injec-
tions and fillers, and filler reactions and combinations and variations 
of these terms. The anatomy of the periorbital and perioral zones 
was also searched and explored to assess any unusual aspects of 
these sphincter muscles that may contribute to adverse issues.
5  | RESULTS
Results from these searches raised some concerns about adverse 
reactions both by the possibility of intravascular injection and ex-
travascular reactions and repositioning of product relating to inject-
ing filler materials into the mimetic muscles.
6  | DISCUSSION
The issues with the muscular layer and fillers.
6.1 | Vascular issues
These periorificial muscles are dynamic and very active mus-
cles. They have abundant blood supply and important vascular 
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connections. This is seen by the frequency of bruising on inject-
ing either around the eyes and the mouth. In the perioral area, the 
large vessels of the inferior and superior labial arteries along with 
the mental and submental all are potential embolic targets.8,9 These 
tend to run either just superior or inferior to the muscles of the 
perioral region. There is much variability of vascular architecture 
within the horizontal layer but far less variability in their depth. It 
is thus advisable to keep away from these structures by gleaning 
an understanding of vascular anatomy in each area of injection and 
maintaining a respectful distance from major vessels. However, even 
depth is imperfect, with variability in the superior labial artery from 
its usual plane in greater than 20% of cadavers10 being between the 
orbicularis muscle and the mucosa in 78%, between the superficial 
and deep parts of the orbicularis muscle in 17.5% and superficial to 
the muscle (between the skin and the orbicularis muscle in 2.1%). As 
the vessels tend to track the muscles rather intimately, keeping clear 
of these structures would seem prudent. A notable exception to this 
variation of vascular anatomy and where depth is fixed pertains to 
the emergence of the supratrochlear, supraorbital, zygomaticofacial, 
zygomaticotemporal, infraorbital, and mental arteries through their 
foramina. These regions should be avoided at depth or approached 
in a fashion to minimize the chance of intravascular injection. Around 
the eyes, vascular supply emanates from the facial and superficial 
temporal as well as the ophthalmic arteries.11 Similarly, it is usually 
advised around the eyes that deep injection below the muscular 
layer or superficial injection above it are safer options than intra-
muscular injections. However, medially in the tear trough, this is not 
practical as the muscle is tightly bound to the periosteum.12
6.2 | Mechanical effects
The periorificial muscles act as squeezing muscles closing their ori-
ficial structures. Any material implanted in these structures is likely 
to be displaced. This may lead to anterior displacement of product 
in the infraorbital zone if it is placed into the muscles. Added to this, 
injection even if intended to be deep may in fact be intramuscular in 
this zone.
13,14 In the perioral zone, constant muscle movement, which 
cannot be prevented during speech and mastication, can compress 
an injected linear strand to a lump. Therefore, intramuscular injection 
may lead to clumping and increase the chance of nodule formation 
with Poly-L-Lactic Acid. The incidence appears to be reduced when 
the perioral and periorbital zones are avoided.15,16 It is suggested 
by manufacturers of Calcium hydroxyapatite and acrylate fillers that 
the regions around the eyes and mouth are not targeted.17,18 It is un-
known at this time whether the higher incidence of clumping or nod-
ules with these products is because the intramuscular injection is 
specifically the risk or the higher movement or metabolic activity of 
these areas or other the effect of unknown factors. Autologous fat 
injection into muscles was a technique described close to 20 years 
ago but has not been described often over recent years.
19,20
In addition, the muscles of facial expression lack an envelop-
ing fascia, that is, epimysium with the exception of the buccinator 
muscle. Furthermore, most of the facial muscles change planes from 
layer 5 to layer 2 in the face.21 Thus theoretically, the filling sub-
stance may not remain contained within the muscle where initially 
placed but may over time end up in multiple planes or extruded from 
the muscle.
6.3 | Metabolic effects
The metabolic activity inherent in the musculature and its support-
ing vasculature may support vigorous inflammatory responses once 
initiated. A strict sterile, or clean environment, is difficult to maintain 
in the perioral zone prior to, during, and after procedure, and intro-
duction of bacteria is likely with all injections. It is probable that the 
periphery of the filler injected is what is subjected initially and over 
time to degradative forces via specific enzymes such as hyaluroni-
dase and reactive oxygen species via inflammation. The continual 
mechanical distortion of boluses of material may break down larger 
clumps of fillers exposing them to more metabolic activity and po-
tential inflammatory effects.
6.4 | Specific use of hyaluronic acid fillers
As most injections in these regions are now hyaluronic acid, it is use-
ful to look at the recent literature in relation to delayed nodules with 
these agents. Both regions are susceptible to late nodule develop-
ment with this agent.
The preceding discussion is very pertinent to these agents. It 
is likely that over time the following may occur. Over the weeks or 
months after injection, a bolus of hyaluronic acid (HA) filler may 
be expected to be degraded on the periphery of the bolus by local 
enzymatic activity and inflammatory mediators. All HA filler ma-
terials start as high molecular weight hyaluronic acid compounds 
(>1000 kDa). Some fillers have lower hyaluronic HA (>500 kDa) in 
combination with high molecular weight HA but even this is far away 
from low molecular weight HA (10-250 kDa). Low molecular weight 
HA (10-20 kDa) is the eventual breakdown product of all HA prod-
ucts, and if this occurs at a normal rate, it will be seen as gradual loss 
of filler volume over time.
Current observation shows that a bolus of filler if implanted 
within muscle may follow a different cascade. Over time, the 
periphery will be exposed to normal metabolic degradation, but 
mechanical effects may induce change in, or magnification of the 
filler surface area over time. In one study, 5 of 7 explanted facial 
implants demonstrated biofilm formation under electron micros-
copy, and rougher, more porous surfaces displayed more severe 
biofilm formation than smoother implants. Theoretically, this 
could be extrapolated to HA filler in the above circumstance.22,23 
In the presence of either implanted bacteria or hematogenous de-
rived pathogens at the periphery of the filler, the resultant inflam-
mation to this infection will cause accelerated degradation of the 
HA filler to low molecular weight hyaluronic acid. Low molecular 
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weight HAs are pro-inflammatory and may create a feedback loop 
inducing further inflammation. A case report describes progres-
sively worsening eyelid edema with histopathological evidence 
of degenerating striated muscle surrounding pools of hyaluronic 
acid.24 Chronic inflammation or toxicity secondary to filler break-
down products were put forward as possible explanations.
25,26 
Certain HA agents may be more prone to this activation than 
others. Certain patients may be able to mount reactions more 
significantly than other patients and the infective agent will il-
licit differing effects depending on its relative virulence. Injecting 
into muscles is likely in both the periorbital and perioral zones 
to create a suitable environment amplifying the likelihood of this 
activity.
6.5 | Injecting the perioral and periorbital zones
To decrease the rate of delayed nodules in these areas, it is best to 
lay down very small aliquots or layers that may be more difficult to 
clump or alter with mechanical movement. It is advisable to inject 
slowly to decrease trauma to the tissues and to avoid intravascu-
lar injection. It is imperative that sterility is maximized especially in 
the perioral area. This includes complete face washing and recurrent 
use of antiseptics locally throughout the injection process. It may be 
that in the current COVID-19 pandemic that use of mouth, nose, and 
eye antiviral irrigation may become commonplace. From the fore-
going discussion, avoiding the muscular layer is also recommended. 
All this becomes more important when using certain product lines. 
HA products are possibly not all the same. Some may have a higher 
rate of issues than others and many may have a higher rate of issues 
when introduced to a market than they do after market experience. 
In jurisdictions where teaching has been to avoid the muscular layer, 
large boluses and rapid injections the complication rate appears to 
be less.
6.6 | COVID-19 and periorificial treatment
There is now an additional confounder for injecting in the perioral 
and periorbital zone, the risk of contamination in a patient carrying 
or presymptomatic of COVID-19. Although not common, COVID-
19 has been found in ocular secretions with reports of ophthal-
mologists and otolaryngologists dying of coronavirus.27 The nose 
and surrounding zones and the mouth and perioral area are more 
concerning28 especially as fillers in these areas are so common. 
Treatment of these areas may be problematic at this time but if 
they are attempted, decreasing viral load with mouth rinses and 
nasal applications may be an important consideration.29
ORCID
Greg J. Goodman  https://orcid.org/0000-0003-4089-9690 
Firas Al-Niaimi  https://orcid.org/0000-0002-0684-4322 
R E FE R E N C E S
 1. Beleznay K, Carruthers JDA, Humphrey S, Carruthers A, Jones D. 
Update on avoiding and treating blindness from fillers: a recent re-
view of the world literature. Aesthet Surg J. 2019;39(6):662-674.
 2. Chatrath V, Banerjee PS, Goodman GJ, Rahman E. Soft-tissue 
filler–associated blindness. Plast Reconstr Surg Glob Open. 
2019;7(4):e2173.
 3. Humphrey S, Jones DH, Carruthers J, et al. Retrospective review of 
delayed adverse events secondary to treatment with a smooth, co-
hesive 20-mg/mL hyaluronic acid filler in 4500 patients. J Am Acad 
Dermatol. 2020.https://doi.org/10.1016/j.jaad.2020.01.066 
 4. Chiang YZ, Pierone G, Al-Niaimi F. Dermal fillers: pathophysiology, 
prevention and treatment of complications. J Eur Acad Dermatol 
Venereol. 2017;31(3):405-413.
 5. Ashton MW, Taylor GI, Corlett RJ. The role of anastomotic vessels 
in controlling tissue viability and defining tissue necrosis with spe-
cial reference to complications following injection of hyaluronic 
acid fillers. Plast Reconstr Surg. 2018;141(6):818e-830e.
 6. Tong J, Patel BC. Anatomy, Head and Neck, Eye Orbicularis Oculi 
Muscle. In: StatPearls [Internet]. Treasure Island, FL: StatPearls 
Publishing; 2020. Available from https://www.ncbi.nlm.nih.gov/
books /NBK44 1907/
 7. Jain P, Rathee M. Anatomy, Head and Neck, Orbicularis Oris Muscle. 
In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 
2019. Available from https://www.ncbi.nlm.nih.gov/books /NBK54 
5169/
 8. Tansatit T, Apinuntrum P, Phetudom T. A typical pattern of the labial 
arteries with implication for lip augmentation with injectable fillers. 
Aesthetic Plast Surg. 2014;38(6):1083-1089.
 9. Tansatit T, Apinuntrum P, Phetudom T. Cadaveric assessment of 
lip injections: locating the serious threats. Aesthetic Plast Surg. 
2017;41(2):430-440.
 10. Cotofana S, Pretterklieber B, Lucius R. Distribution pattern of 
the superior and inferior labial arteries: impact for safe upper 
and lower lip augmentation procedures. Plast Reconstr Surg. 
2017;139(5):1075-1082.
 11. Jitaree B, Phumyoo T, Uruwan S, Sawatwong W, McCormick L, 
Tansatit T. The feasibility determination of risky severe complica-
tions of arterial vasculature regarding the filler injection sites at the 
tear trough. Plast Reconstr Surg. 2018;142(5):1153-1163.
 12. Yang N, Qiu W, Wang Z, Su X, Jia H, Shi H. [Anatomical studying of 
the tear trough area]. Article in Chinese. Zhonghua Zheng Xing Wai 
Ke Za Zhi. 2014;30(1):50-53.
 13. van Loghem JAJ, Humzah D, Kerscher M. Cannula versus sharp 
needle for placement of soft tissue fillers: an observational cadaver 
study. Aesthet Surg J. 2016;38(1):73-88.
 14. Lowe NJ, Maxwell AC, Lowe P, Shah A, Patnaik R. Injectable po-
ly-l-lactic acid. Dermatol Surg. 2009;35(Sup 1):344-349.
 15. https://www.acces sdata.fda.gov/cdrh_docs/pdf2/p0200 12s00 
9d.pdf
 16. Vleggaar D. Poly-L-lactic acid: consultation on the injection tech-
niques. J Eur Acad Dermatol Venereol. 2006;20(Suppl 1):17-21.
 17. Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapa-
tite-based implant (Radiesse) for facial soft-tissue augmenta-
tion. Plast Reconstr Surg. 2006;118(Suppl):22S-30S. discussion 
31S–33S.
 18. Tzikas TL. A 52-month summary of results using calcium hy-
droxylapatite for facial soft tissue augmentation. Dermatol Surg. 
2008;34(Suppl 1):S9-S15.
 19. Butterwick KJ. Fat autograft muscle injection (FAMI): new tech-
nique for facial volume restoration. Dermatol Surg. 2005;31(11 Pt 
2):1487-1495.
 20. Amar RE, Fox DM. The facial autologous muscular injection 
(FAMI) procedure: an anatomically targeted deep multiplane 
1850  |     GOODMAN et Al.
autologous fat-grafting technique using principles of facial fat in-
jection. Aesthetic Plast Surg. 2011;35(4):502-510.
 21. Cotofana S, Fratila AA, Schenck TL, Redka-Swoboda W, Zilinsky I, 
Pavicic T. The anatomy of the aging face: a review. Facial Plast Surg. 
2016;32:253-260.
 22. Ibrahim O, Overman J, Arndt K, Dover J. Filler nodules: inflamma-
tory or infectious? A review of biofilms and their implications on 
clinical practice. Dermatol Surg. 2018;44:53-60.
 23. Walker TJ, Toriumi DM. Analysis of facial implants for bacterial 
biofilm formation using scanning electron microscopy. JAMA Facial 
Plast Surg. 2016;18:299-304.
 24. Teo AA, Mokhtarzadeh A, Cameron JD, Harrison AR. Late pre-
sentation of enlarging lower eyelid mass and muscle degeneration 
secondary to hyaluronic acid filler. Ophthal Plast Reconstr Surg. 
2017;33(3S):S9-S11.
 25. SkippenB Baldelli I, Hartstein M, Casabona G, Montes JR, Bernardini 
F. Rehabilitation of the dysmorphic lower eyelid from hyaluronic 
acod filler: what to do after a good periocular treatment goes bad. 
Aesthet Surg J. 2019;40:197-205.
 26. De Pasquale A, Russa G, Pulvirenti M, Di Rosa L. Injection technique 
and high-frequency ultrasound follow-up evaluation. Aesthetic Plast 
Surg. 2013;37:587-591.
 27. Chen M-J, Chang K-J, Hsu C-C, Lin P-Y, Liu CJ-L. Precaution and 
prevention of coronavirus disease 2019 (COVID-19) infection 
in the eye. J Chin Med Assoc. 2020:1.https://doi.org/10.1097/
JCMA.00000 00000 000334
 28. Hao XU, Zhong L, Deng J, et al. High expression of ACE2 receptor 
of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 
2020;12(1):8.
 29. Carrouel F, Conte MP, Fisher J, et al. COVID-19: a recommenda-
tion to examine the effect of Mouthrinses with β-Cyclodextrin 
combined with citrox in preventing infection and progression. J Clin 
Med. 2020;9(4):1126.
How to cite this article: Goodman GJ, Al-Niaimi F, McDonald 
C, Ciconte A, Porter C. Why we should be avoiding periorificial 
mimetic muscles when injecting tissue fillers. J Cosmet 
Dermatol. 2020;19:1846–1850. https://doi.org/10.1111/
jocd.13531
